[Form 4] Shuttle Pharmaceuticals Holdings, Inc. Insider Trading Activity
George Scorsis, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 Restricted Stock Units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock. The award is reported as direct beneficial ownership by the reporting person.
One-third of the RSUs vest on each of 08/08/2026, 08/08/2027 and 08/08/2028, meaning up to 29,240 common shares may be issued to satisfy the award over three years if vesting conditions are met. The grant is a standard equity compensation award for a board member with a multi-year retention schedule.
George Scorsis, direttore di Shuttle Pharmaceuticals Holdings (SHPH), ha ricevuto 29.240 Restricted Stock Units (RSU) in data 08/08/2025. Ciascuna RSU conferisce il diritto condizionato a ricevere una azione ordinaria. L'assegnazione 猫 dichiarata come titolarit脿 beneficiaria diretta dalla persona che ha presentato la segnalazione.
Un terzo delle RSU matura il 08/08/2026, il 08/08/2027 e il 08/08/2028; pertanto, fino a 29.240 azioni ordinarie potranno essere emesse per soddisfare l'assegnazione nell'arco di tre anni se vengono rispettate le condizioni di maturazione. Il conferimento 猫 una normale forma di compenso azionario per un membro del consiglio con un piano di retention pluriennale.
George Scorsis, director de Shuttle Pharmaceuticals Holdings (SHPH), recibi贸 29.240 Restricted Stock Units (RSU) el 08/08/2025. Cada RSU representa el derecho condicionado a recibir una acci贸n ordinaria. La adjudicaci贸n se informa como propiedad beneficiaria directa por parte de la persona que realiza la declaraci贸n.
Un tercio de las RSU vence el 08/08/2026, el 08/08/2027 y el 08/08/2028; por tanto, se podr铆an emitir hasta 29.240 acciones ordinarias para satisfacer la adjudicaci贸n a lo largo de tres a帽os si se cumplen las condiciones de consolidaci贸n. La concesi贸n es una compensaci贸n accionaria est谩ndar para un miembro del consejo con un plan de retenci贸n plurianual.
George Scorsis電� Shuttle Pharmaceuticals Holdings(SHPH)鞚� 鞚挫偓搿滌劀 2025/08/08鞐� 29,240臧滌潣 鞝滍暅臁瓣贝攵� 欤检嫕 雼渼(RSUs)毳� 攵�鞐皼鞎橃姷雼堧嫟. 臧� RSU電� 氤错喌欤� 1欤茧ゼ 氚涭潉 靾� 鞛堧姅 臁瓣贝攵� 甓岆Μ毳� 霚豁暕雼堧嫟. 頃措嫻 靾橃棳電� 鞁犼碃鞚胳棎 鞚橅暣 歆侅爲鞝侅澑 鞁れ 靻岇湢搿� 氤搓碃霅橃棃鞀惦媹雼�.
RSU鞚� 3攵勳潣 1鞚� 2026/08/08, 2027/08/08 氚� 2028/08/08鞐� 臧侁皝 氩犾姢韺呺悩氅�, 氩犾姢韺� 臁瓣贝鞚� 於╈”霅� 瓴届毎 3雲� 霃欖晥 斓滊寑 29,240欤检潣 氤错喌欤缄皜 氚滍枆霅橃柎 靾橃棳毳� 於╇嫻頃� 靾� 鞛堨姷雼堧嫟. 鞚措矆 攵�鞐姅 雼る厔臧� 鞙犾 鞚检爼鞚� 韽暔霅� 鞚挫偓須� 甑劚鞗� 雽�靸侅潣 響滌 欤检嫕 氤挫儊鞛呺媹雼�.
George Scorsis, administrateur de Shuttle Pharmaceuticals Holdings (SHPH), s'est vu accorder 29 240 Restricted Stock Units (RSU) le 08/08/2025. Chaque RSU repr茅sente le droit conditionnel de recevoir une action ordinaire. L'attribution est d茅clar茅e comme propri茅t茅 b茅n茅ficiaire directe par la personne d茅clarante.
Un tiers des RSU acquiert des droits le 08/08/2026, le 08/08/2027 et le 08/08/2028 ; ainsi, jusqu'脿 29 240 actions ordinaires pourront 锚tre 茅mises pour satisfaire l'attribution sur une p茅riode de trois ans si les conditions d'acquisition sont remplies. Cette attribution constitue une r茅mun茅ration en actions standard pour un membre du conseil avec un calendrier de r茅tention pluriannuel.
George Scorsis, Direktor von Shuttle Pharmaceuticals Holdings (SHPH), wurde am 08.08.2025 29.240 Restricted Stock Units (RSUs) gew盲hrt. Jede RSU verbrieft bedingt das Recht auf den Erhalt einer Stammaktie. Die Gew盲hrung ist vom meldenden Gesch盲ftstr盲ger als direkte wirtschaftliche Eigent眉merschaft gemeldet.
Ein Drittel der RSUs wird am 08.08.2026, 08.08.2027 und 08.08.2028 unverfallbar, sodass bei Erf眉llung der Vesting-Bedingungen innerhalb von drei Jahren bis zu 29.240 Stammaktien ausgegeben werden k枚nnen. Die Zuteilung ist eine 眉bliche aktienbasierte Verg眉tung f眉r ein Vorstandsmitglied mit einem mehrj盲hrigen Bindungsplan.
- 29,240 RSUs granted to director George Scorsis
- Vesting schedule is explicit: one-third on 08/08/2026, 08/08/2027 and 08/08/2028
- None.
Insights
TL;DR: Routine director equity grant of 29,240 RSUs with three-year vesting; governance impact appears standard and non-disruptive.
The Form 4 shows a non-derivative-based equity compensation award in the form of 29,240 Restricted Stock Units granted to director George Scorsis on 08/08/2025. The RSUs are direct beneficial ownership and vest one-third annually on 08/08/2026, 08/08/2027 and 08/08/2028. From a governance perspective, this is a typical retention and alignment mechanism for a board member. The filing does not disclose any accelerated vesting triggers or related-party transaction terms beyond the basic grant and schedule, so material governance concerns are not evident from the document alone.
TL;DR: A standard RSU award totaling 29,240 units with staged vesting over three years; compensation outcomes depend on settlement terms not detailed here.
The report specifies 29,240 RSUs, each converting to one share upon vesting, exercisable under a schedule of one-third on each of 08/08/2026, 08/08/2027 and 08/08/2028. The conversion price is shown as $0, consistent with RSUs that settle in shares rather than requiring purchase. The Form 4 indicates direct ownership post-grant. The filing lacks additional compensation plan details such as performance conditions, settlement timing, or withholding treatment, so assessment of total cost or dilutive impact to shareholders cannot be quantified from this document alone.
George Scorsis, direttore di Shuttle Pharmaceuticals Holdings (SHPH), ha ricevuto 29.240 Restricted Stock Units (RSU) in data 08/08/2025. Ciascuna RSU conferisce il diritto condizionato a ricevere una azione ordinaria. L'assegnazione 猫 dichiarata come titolarit脿 beneficiaria diretta dalla persona che ha presentato la segnalazione.
Un terzo delle RSU matura il 08/08/2026, il 08/08/2027 e il 08/08/2028; pertanto, fino a 29.240 azioni ordinarie potranno essere emesse per soddisfare l'assegnazione nell'arco di tre anni se vengono rispettate le condizioni di maturazione. Il conferimento 猫 una normale forma di compenso azionario per un membro del consiglio con un piano di retention pluriennale.
George Scorsis, director de Shuttle Pharmaceuticals Holdings (SHPH), recibi贸 29.240 Restricted Stock Units (RSU) el 08/08/2025. Cada RSU representa el derecho condicionado a recibir una acci贸n ordinaria. La adjudicaci贸n se informa como propiedad beneficiaria directa por parte de la persona que realiza la declaraci贸n.
Un tercio de las RSU vence el 08/08/2026, el 08/08/2027 y el 08/08/2028; por tanto, se podr铆an emitir hasta 29.240 acciones ordinarias para satisfacer la adjudicaci贸n a lo largo de tres a帽os si se cumplen las condiciones de consolidaci贸n. La concesi贸n es una compensaci贸n accionaria est谩ndar para un miembro del consejo con un plan de retenci贸n plurianual.
George Scorsis電� Shuttle Pharmaceuticals Holdings(SHPH)鞚� 鞚挫偓搿滌劀 2025/08/08鞐� 29,240臧滌潣 鞝滍暅臁瓣贝攵� 欤检嫕 雼渼(RSUs)毳� 攵�鞐皼鞎橃姷雼堧嫟. 臧� RSU電� 氤错喌欤� 1欤茧ゼ 氚涭潉 靾� 鞛堧姅 臁瓣贝攵� 甓岆Μ毳� 霚豁暕雼堧嫟. 頃措嫻 靾橃棳電� 鞁犼碃鞚胳棎 鞚橅暣 歆侅爲鞝侅澑 鞁れ 靻岇湢搿� 氤搓碃霅橃棃鞀惦媹雼�.
RSU鞚� 3攵勳潣 1鞚� 2026/08/08, 2027/08/08 氚� 2028/08/08鞐� 臧侁皝 氩犾姢韺呺悩氅�, 氩犾姢韺� 臁瓣贝鞚� 於╈”霅� 瓴届毎 3雲� 霃欖晥 斓滊寑 29,240欤检潣 氤错喌欤缄皜 氚滍枆霅橃柎 靾橃棳毳� 於╇嫻頃� 靾� 鞛堨姷雼堧嫟. 鞚措矆 攵�鞐姅 雼る厔臧� 鞙犾 鞚检爼鞚� 韽暔霅� 鞚挫偓須� 甑劚鞗� 雽�靸侅潣 響滌 欤检嫕 氤挫儊鞛呺媹雼�.
George Scorsis, administrateur de Shuttle Pharmaceuticals Holdings (SHPH), s'est vu accorder 29 240 Restricted Stock Units (RSU) le 08/08/2025. Chaque RSU repr茅sente le droit conditionnel de recevoir une action ordinaire. L'attribution est d茅clar茅e comme propri茅t茅 b茅n茅ficiaire directe par la personne d茅clarante.
Un tiers des RSU acquiert des droits le 08/08/2026, le 08/08/2027 et le 08/08/2028 ; ainsi, jusqu'脿 29 240 actions ordinaires pourront 锚tre 茅mises pour satisfaire l'attribution sur une p茅riode de trois ans si les conditions d'acquisition sont remplies. Cette attribution constitue une r茅mun茅ration en actions standard pour un membre du conseil avec un calendrier de r茅tention pluriannuel.
George Scorsis, Direktor von Shuttle Pharmaceuticals Holdings (SHPH), wurde am 08.08.2025 29.240 Restricted Stock Units (RSUs) gew盲hrt. Jede RSU verbrieft bedingt das Recht auf den Erhalt einer Stammaktie. Die Gew盲hrung ist vom meldenden Gesch盲ftstr盲ger als direkte wirtschaftliche Eigent眉merschaft gemeldet.
Ein Drittel der RSUs wird am 08.08.2026, 08.08.2027 und 08.08.2028 unverfallbar, sodass bei Erf眉llung der Vesting-Bedingungen innerhalb von drei Jahren bis zu 29.240 Stammaktien ausgegeben werden k枚nnen. Die Zuteilung ist eine 眉bliche aktienbasierte Verg眉tung f眉r ein Vorstandsmitglied mit einem mehrj盲hrigen Bindungsplan.
FAQ
What did George Scorsis receive according to the SHPH Form 4?
When do the RSUs awarded to the SHPH director vest?
How many shares will be issued if all RSUs to George Scorsis vest?
Is the beneficial ownership reported as direct or indirect in the SHPH filing?
Was this Form 4 filed by a single reporting person for SHPH?
